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ABSTRACT
Objective: To investigate whether a serotonin-to-dopamine terminal ratio is related to the appear-
ance of dyskinesias in patients with Parkinson disease (PD).
Methods: Twenty-eight patients with idiopathic PD (17 with levodopa-induced dyskinesias [LIDs],
11 without dyskinesias) and 12 age-matched healthy controls were studied with PET and 5[11C]-
3-amino-4-(2-dimethylaminomethylphenyl-sulfanyl)-benzonitrile (11C-DASB) andwith SPECT and
[123I]N-w-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)nortropane (123I-ioflupane), which are
in vivo specific markers of the serotonin and dopamine transporters’ availability, respectively. We
have employed a simplified reference tissue model for the quantification of 11C-DASB, whereas a
semiquantification approach was used for 123I-ioflupane data. We calculated 11C-DASB binding
to 123I-ioflupane uptake ratios for the caudate and the putamen.
Results: Patients with PD showed striatal decreases in 11C-DASB binding potential (p, 0.01) and
in 123I-ioflupane mean uptake (p , 0.001) compared to controls. The mean 11C-DASB binding to
123I-ioflupane uptake ratio in the putamen was 0.779 (increased by 75.8% of the controls’ mean)
for the nondyskinetic group and 0.901 (increased by 103.4% of the controls’ mean) for the
patients with dyskinesias. There was a statistically significant difference (p , 0.001) in 11C-
DASB binding to 123I-ioflupane uptake ratio in the putamen between the group of patients with
and without dyskinesias. Higher 11C-DASB to 123I-ioflupane binding ratios correlated with longer
disease duration for the 28 patients with PD (r 5 0.52; p , 0.01).
Conclusions: Serotonin-to-dopamine transporter binding ratio increases as PD progresses and
patients experience LIDs. Our findings suggest that, when the dopaminergic innervation in the
striatum is critically low, the serotonergic system plays an important role in development of
LIDs. Neurology® 2016;86:1–7
GLOSSARY
AIMS 5 Abnormal Involuntary Movement Scale; BP 5 binding potential; 11C-DASB 5 5[11C]-3-amino-4-(2-
dimethylaminomethylphenyl-sulfanyl)-benzonitrile; DAT 5 dopamine transporter; HAM-D 5 Hamilton Depression Rating
Scale; 123I-ioflupane 5 [123I]N-w-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)nortropane; LID 5 L-dopa-induced dyski-
nesia; MMSE 5 Mini-Mental State Examination; PD 5 Parkinson disease; ROI 5 region of interest; SERT 5 serotonin
transporter; UPDRS 5 Unified Parkinson’s Disease Rating Scale; VDR 5 volume of distribution ratio.
Studies in the animal model of Parkinson disease (PD)1 as well as in humans2–4 have indicated
that degeneration of dopaminergic presynaptic terminals in the striatum is critical in the devel-
opment of L-dopa-induced dyskinesias (LIDs). Due to the progressive degeneration, striatal
dopaminergic terminals lose their dopamine storage capacity and the ability to maintain a stable
dopamine release rate in the synapse.5
Serotonergic terminals have been found capable of converting exogenous levodopa into dopa-
mine, store it in synaptic vesicles, and release it in an activity-dependent manner.6–9 The above
studies propose that serotonergic terminals in the degenerating striatum are responsible for
mishandling exogenous levodopa and exacerbating dyskinesia in the animal model10–12 and
PD.13 Accordingly, the presence of dyskinesia could be a reflection of serotonergic over
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dopaminergic terminals’ activity. Nonetheless,
the above mechanisms have not been fully
understood in humans.
Dopamine transporter (DAT) and serotonin
transporter (SERT) are densely located in the
presynaptic terminals in the striatum.14,15 The
SPECT tracer [123I]N-w-fluoropropyl-2b-car-
bomethoxy-3b-(4-iodophenyl)nortropane
(123I-ioflupane) and the PET ligand 5[11C]-
3-amino-4-(2-dimethylaminomethylphenyl-
sulfanyl)-benzonitrile (11C-DASB) are in vivo
specific markers of DAT16 and SERT17 avail-
abilities. This study intended to assess the
interaction of dopaminergic and serotonergic
presynaptic mechanisms in the development
of LIDs. We hypothesized that a SERT-to-
DAT ratio in the striatum is related to
the occurrence of LIDs and employed the
above imaging techniques with 11C-DASB
and 123I-ioflupane to assess this ratio.
METHODS Standard protocol approvals, registrations,
and patient consents. All participants provided their written
consent in accordance with the Declaration of Helsinki. This
study was reviewed and approved by the West London Research
Ethics Committee, the Imperial College Joint Research Compli-
ance Office, and the Administration of Radioactive Substances
Advisory Committee, UK.
Participants. Patients with PD were recruited from our Move-
ment Disorders Clinic at the Imperial College Healthcare NHS
Trust, London, UK. Patients with PD fulfilled the UK Brain
Bank Criteria for idiopathic PD.18 At screening, patients with
PD were on levodopa treatment for at least 2 years. Patients with
a history of dementia or depression were excluded from this
study. Clinical data were acquired by detailed medical history
including medication history cross-checked with patients’
medical notes and clinical letters to their general practitioners.
Patients with PD were assessed in an outpatient clinical setting for
their motor and nonmotor symptoms including the Unified
Parkinson’s Disease Rating Scale (UPDRS) and the modified
Hoehn & Yahr staging scale.
All participants were assessed for depression using the Ham-
ilton Depression Rating Scale (HAM-D) and for cognitive
impairment using the Mini-Mental State Examination (MMSE).
None of the patients with PD had a history of depression and
HAM-D scores above 7 were an exclusion criterion. Patients with
PD with cognitive impairment were excluded from this study; an
MMSE score below 26 was an exclusion criterion.
Thirty-six patients with idiopathic PD were screened for
enrollment in the study, 6 of whom failed one of the exclusion
criteria, and 2 declined participation in the study. Twenty-eight
patients with idiopathic PD were included in the study. Seven-
teen patients experienced LIDs and 11 did not experience LIDs.
Clinical evaluation. Presence of LIDs was then assessed on sep-
arate days within 1 hour after the patients had taken their usual
levodopa dose (range of single dose: 100–200 mg). LIDs were
scored using the Abnormal Involuntary Movement Scale (AIMS)
every 15 minutes for the next 120 minutes.
The LEDTotal, LEDLdopa, and LEDDag doses were calculated
in milligrams for each individual following the formulas13
described in table e-1 on the Neurology® Web site at
Neurology.org. DDdiagn was defined as the time from the date
of the PD diagnosis at the movement disorders clinic and DDonset
as the time since each individual first experienced a PD motor
symptom. At the time of diagnosis, all patients with PD were
classified as stage 1 on the modified Hoehn & Yahr staging scale.
We also calculated the time from diagnosis to initiation of dopa-
minergic medication per individual. None of the patients with
PD was treated with any drugs that directly act on the serotoner-
gic system.
We also included 12 healthy controls who undertook the
same imaging procedures as described below (table 1).
Scanning procedures. All participants had brain SPECT imag-
ing with 123I-ioflupane and brain PET imaging with 11C-DASB.
All participants also had a 1.5 T1-weighted MRI scan for
coregistration to the PET imaging data.
Patients with PD were asked to withdraw frommedication 18
hours prior to any procedure involving ionizing radiation and this
was defined as the “off” dopaminergic medication state. All pa-
tients with PD were assessed for motor symptoms with the
UPDRS part III scale in “off” dopaminergic medication state.
All imaging were performed at the Hammersmith and Char-
ing Cross Hospitals of Imperial College in London.
11C-DASB PET scan images were obtained with an EXAT
EXACT HR1 scanner (Siemens; Munich, Germany) and details
on the PET and MRI scanners have been described previously.17
Briefly, patients with PD underwent a low-dose CT brain scan
prior to the administration of the 11C-DASB PET tracer to mea-
sure tissue attenuation of radiation. A mean activity dose of 450
MBq was administered to each individual undertaking
a 11C-DASB PET scan. PET images were obtained for 90 minutes
starting after IV bolus injection of the PET tracer.
For the administration of 123I-ioflupane, thyroid gland block-
ade was performed by administering potassium iodide tablets
60 mg twice daily for 3 consecutive days, starting 24 hours prior
to the SPECT scan day, in accordance with the clinical protocol
of our nuclear medicine department. All 123I-ioflupane SPECT
scan images were obtained with a Symbia T SPECT-CT scanner
(Siemens). A mean activity dose of 185 MBq was administered to
each individual undergoing a 123I-ioflupane SPECT scan. SPECT
images were obtained 180 minutes after IV bolus injection
of 123I-ioflupane for approximately 45 minutes.
11C-DASB PET imaging data analysis. We have employed a
simplified reference tissue model using the cerebellum as the ref-
erence tissue19 for the quantification of 11C-DASB. Following
reconstruction of the dynamic PET image volume, a summed
image volume was created from the entire dynamic dataset using
an in-house software package. A template of high-contrast regions
of interest (ROIs) was defined directly on the summed image and
these ROIs were then applied to the dynamic dataset. Any
movement detected was corrected using a frame-by-frame
realignment procedure. Individual participant MRIs were
coregistered to the summed PET volume using the SPM2
software package (Wellcome Department of Cognitive
Neuroscience, Institute of Neurology) implemented in Matlab
6.5 (MathWorks; Natick, MA). Following coregistration, the
definition of ROIs was performed on the coregistered MRI
using Analyze medical imaging software (version 8.1; Mayo
Foundation; Rochester, NY). ROIs were standardized for
volume throughout and were manually defined for caudate and
putamen. Volume of distribution ratios (VDRs) were computed
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for ROIs with the graphical analysis method of Logan et al.20 and
the binding potential (BP) of the specifically bound PET tracer
relative to the nondisplaceable tracer in tissue was calculated as
VDR-1.21 The specific SERT binding as reflected by 11C-DASB
BP was calculated for each caudate and putamen for both
hemispheres. The average caudate and average putamen
binding was calculated per individual as the mean uptake value
for both hemispheres.
123I-ioflupane SPECT imaging data analysis. A semiquan-
tification analysis approach for each individual was used to
quantify reconstructed tomographic imaging data. Acquired
data were transferred to a HERMES workstation (HERMES
Medical Solutions; Stockholm, Sweden) and reconstructed
with attenuation, scatter, and resolution corrections. The re-
constructed data were analyzed using BRASS software
(HERMES Medical Solutions). The software uses automatic
image registration to align the patient’s image to a template.
This contains a series of predefined volumes of interest that
can be then applied to the image being analyzed. Following
automatic alignment, all scans were inspected visually and
manually realigned to fit to the predefined template where
necessary. Uptake ratios were measured for each caudate and
putamen relative to the nonspecific uptake measured from the
occipital cortex. The uptake is defined as the specific binding
ratio ([striatal counts 2 background counts]/background
counts). The specific DAT binding as reflected by
the 123I-ioflupane uptake values was calculated for each cau-
date and putamen for both hemispheres. The average caudate
and average putamen binding was calculated per individual as
the mean uptake value for both hemispheres.
SERT-to-DAT ratios. We estimated SERT-to-DAT ratios as
reflected by 11C-DASB BP to 123I-ioflupane uptake for the
caudate and the putamen comprising the average caudate and
average putamen uptake values for each individual. SERT-to-
DAT ratios were calculated as described previously in patients
with PD who received neural transplantation.22
Statistical analysis. Statistical analysis and graph illustration was
performed using IBM (Armonk, NY) SPSS (version 22) and
GraphPad (La Jolla, CA) Prism (version 5) software for Windows.
For all variables, we performed normality tests for homogeneity and
Gaussianity with Bartlett and Kolmogorov-Smirnov tests and then
proceeded into parametric tests for all our values that were normally
distributed and nonparametric tests where applicable. For
correlations of the clinical values to the imaging values, we
performed one-tailed Spearman correlations. For specific clinical
characteristics between the groups of PD with and without LIDs,
we calculated 2-tailed p values using unpaired t tests.
RESULTS Clinical findings. The demographics and
clinical characteristics of patients with PD and
healthy controls are summarized in table 1.
Imaging data. The mean uptake of 123I-ioflupane,
11C-DASB BP, and the SERT-to-DAT ratios are
listed in table 2. Representative 11C-DASB PET
Table 1 Demographics and clinical characteristics of patients with PD and healthy controls
Healthy controls PD all Non-LID LID
No. of participants 12 28 11 17
Sex, M:F 7:5 19:9 10:1 9:8
Age at the time of the scan, y 61.41 6 8.64 64.87 6 8.21 69.32 6 4.67 61.69 6 8.89a
MMSE 29.7 6 0.67 28.28 6 1.22 28 6 1.26 28.44 6 1.20
HAM-D 1.8 6 1.62 4.28 6 1.25 4.27 6 0.65 4.28 6 1.53
Disease duration from diagnosis, y — 7.89 6 5.01 5.82 6 4.88 9.56 6 5.48a
Disease duration from onset, y — 9.79 6 4.99 7.82 6 3.66 11.07 6 5.41a
H&Y “off” — 2.34 6 0.57 2.27 6 0.47 2.39 6 0.63
UPDRS-III “off” — 27.59 6 8.32 26.7 6 7.25 28.11 6 9.07
UPDRS total “off” — 45.03 6 10.89 40.55 6 10.30 47.78 6 10.59
Tremor dominant/akinetic-rigid/mixed — 2:15:11 2:5:4 0:10:7
AIMS — — 0 8.06 6 4.26
Duration on dopaminergic medication, y — 6.69 6 4.68 4.41 6 2.07 8.40 6 5.07a
Time from diagnosis to initiation
of DA medication, y
— — 1.45 6 1.05 1.03 6 1.27
Time from PD onset to initiation
of DA medication, y
— — 3.42 6 2.66 2.55 6 1.60
Daily LEDTotal, mg — — 537.59 6 199.87 826.59 6 350.70a
Daily LEDLdopa, mg — — 376.68 6 167.68 650.82 6 369.69
Daily LEDDag, mg — — 160.91 6 193.87 175.76 6 207.02
Abbreviations: AIMS 5 Abnormal Involuntary Movement Scale; DA 5 dopamine; H&Y 5 modified Hoehn & Yahr staging
scale in “off” medication state; HAM-D 5 Hamilton Depression Rating Scale; LID 5 L-dopa-induced dyskinesia; MMSE 5
Mini-Mental State Examination; PD 5 Parkinson disease; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Data represent mean 6 1 SD.
ap , 0.05 between the non-LID and the LID groups.
Neurology 86 March 22, 2016 3
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
and 123I-ioflupane SPECT images at the level of
dorsal basal ganglia in 2 patients with PD with and
without LIDs are shown in figure e-1.
Patients with PD showed reduced 11C-DASB BP
(p, 0.01) in the putamen compared to healthy con-
trols (34%). Patients with PD without LIDs showed
37% loss, while the patients with PD with LIDs
showed 31% loss relative to the mean value of the
healthy controls (between-group comparison for the
putamen; p 5 0.19) (figure 1A). No differences were
found for the caudate (between-group comparison for
the caudate; p 5 0.23) (figure e-2).
Patients with PD showed reduced 123I-ioflupane
uptake values (p , 0.001) compared to healthy con-
trols in the caudate and the putamen. Patients with
PD without LIDs showed 51% loss, while patients
with LIDs showed 62% loss relative to healthy con-
trols (between-group difference for putamen; p 5
0.13) (figure 1B). No differences were found for the
caudate (between-group comparison for the caudate;
p 5 0.16) (figure e-3).
Healthy controls had a mean 11C-DASB BP to
123I-ioflupane uptake ratio in the putamen of 0.443.
All patients with PD had increased 11C-DASB BP to
123I-ioflupane uptake ratio in the putamen compared
to healthy controls (p , 0.001). In particular, pa-
tients with PD with LIDs had a mean 11C-DASB
BP to 123I-ioflupane uptake ratio in the putamen of
0.901 (increased by 103.4% compared to healthy
controls), while in the group of patients without
LIDs, the mean ratio was 0.779 (increased by
75.8%, relative to healthy controls) with a significant
between-group difference (p , 0.001) (figure 1D).
No significant differences were found in the caudate
for the 11C-DASB BP to 123I-ioflupane uptake ratios
(figure 1C).
There was a statistically significant correlation
between putaminal 11C-DASB BP to 123I-ioflupane
uptake ratios and disease duration from diagnosis for
all patients with PD (r 5 0.52; p , 0.01) (figure 2).
No correlation was found between putaminal
11C-DASB BP and either age, UPDRS, AIMS scores,
the mean LEDTotal, the mean LEDLdopa, or the times
from diagnosis to initiation of dopaminergic medica-
tion. No correlation was found between putaminal
123I-ioflupane uptake values and either age, UPDRS,
AIMS scores, the mean LEDTotal, the mean LEDLdopa,
or the times from diagnosis to initiation of dopamin-
ergic medication. No correlation was found between
putaminal 11C-DASB BP to 123I-ioflupane uptake
ratios and either age, UPDRS, AIMS scores, the mean
LEDTotal, the mean LEDLdopa, or the times from diag-
nosis to initiation of dopaminergic medication.
DISCUSSION We found a statistically significant
correlation between the putaminal SERT-to-DAT
ratio and the disease duration in patients with PD.
Our findings indicate that as PD progresses, the
putaminal SERT-to-DAT ratio, as reflected by the
11C-DASB BP to 123I-ioflupane uptake ratio,
becomes higher, thus potentially implicating an
important role for the development of LIDs. We
have shown that the density of DAT in the
putamen of patients with PD with LIDs declines
more than the SERT density compared to patients
without LIDs. These data indicate that as disease
Table 2 Mean uptake values of 123I-ioflupane, 11C-DASB, and the SERT-to-DAT binding
Healthy controls PD all Non-LID LID
No. of participants 12 28 11 17
Region of interest
11C-DASB specific binding (SERT)
Caudate 1.31 6 0.06 0.58 6 0.20a 0.62 6 0.22 0.56 6 0.18
Putamen 1.36 6 0.11 0.90 6 0.25b 0.86 6 0.24 0.94 6 0.22
123I-ioflupane specific to nonspecific binding (DAT)
Caudate 3.42 6 0.44 1.98 6 0.52a 2.10 6 0.49 1.90 6 0.53
Putamen 3.07 6 0.28 1.26 6 0.42a 1.51 6 0.40 1.15 6 0.33
SERT-to-DAT binding ratios
Caudate 0.383 0.304 0.301 0.306
Putamen 0.443 0.851 0.779 0.901c
Abbreviations: 11C-DASB 5 5[11C]-3-amino-4-(2-dimethylaminomethylphenyl-sulfanyl)-benzonitrile; DAT 5 dopamine
transporter; 123I-ioflupane 5 [123I]N-w-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl)nortropane; LID 5 L-dopa-induced
dyskinesia; PD 5 Parkinson disease; SERT 5 serotonin transporter.
Data represent mean 6 1 SD. Mean values are calculated as an average for both hemispheres.
ap , 0.01 between the PD and the healthy controls group.
bp , 0.05 between the PD and the healthy controls group.
cp , 0.001 between the non-LID and LID groups.
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progresses, SERT over DAT availabilities increase
in the striatum and that it is the ratio rather than
the DAT/SERT components of it that may be
important for the appearance of dyskinesias in
advanced disease.
As PD progresses, reductions in striatal DAT den-
sity have been proposed to support presynaptic mech-
anisms as responsible for the development of LIDs
due to the subsequent loss of dopamine storage capac-
ity.5 Patients with advanced PD lose their ability to
maintain a stable rate of dopamine release in the stri-
atum. Thus, the dopamine release is fairly dependent
on the levodopa delivery rate into the synapse.
PET studies with 11C-raclopride, which reflects
postsynaptic dopamine D2 receptor distribution, are
able to estimate in vivo the dopamine release in the
striatum.23 Tedroff et al.2 have shown that the same
dose of exogenous levodopa can induce higher levels
of synaptic dopamine in advanced PD in comparison
to early disease. Furthermore, standard levodopa
doses can cause high swings in synaptic dopamine
increases in PD with LIDs,3 the magnitude of which
correlated with higher dyskinesia scores.4
Wide fluctuations in the synaptic concentration of
dopamine in patients with motor fluctuations have
been also shown to precede clinically apparent LIDs24
and were linked with longer disease duration and a
younger age at onset.25
Figure 2 Correlation of serotonin transporter
(SERT)–to–dopamine transporter
(DAT) binding ratios and disease
duration in 28 patients with Parkinson
disease (PD)
Statistical analysis was performed with one-tailed Spear-
man correlation between disease duration from diagnosis
(in years) and SERT-to-DAT binding ratios in the putamen
of 28 patients with PD (r 5 0.521, p , 0.01). Each point
in the graph represents one patient with PD.
Figure 1 Histograms of mean uptake values of 123I-ioflupane, 11C-DASB binding, and serotonin transporter
(SERT)-to-dopamine transporter (DAT) binding
(A) Histogram of mean 11C-DASB binding for the putamen shown in 12 healthy controls (HCs), the Parkinson disease PD
non–L-dopa-induced dyskinesia (LID) group (n 5 11), and the PD LID group (n 5 17). (B) Histogram of mean 123I-ioflupane
binding for the putamen shown in 12 HCs, the PD non-LID group (n 5 11), and the PD LID group (n 5 17). (C) Histogram of
mean SERT-to-DAT binding ratios calculated for the caudate in 12 HCs, non-LID (n 5 11), and LID (n 5 17). (D) Histogram
of mean SERT-to-DAT binding ratios calculated for the putamen in 12 HCs, non-LID (n 5 11), and LID (n 5 17). Data
represent mean 6 1 SD. Mean values are calculated as an average for both hemispheres. ***Statistical significance (p ,
0.001). NS 5 not significant.
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Alongside these dopaminergic mechanisms, sero-
tonergic terminals in the striatum have been shown
to be also involved in the development of LIDs.
In experimental animals, the chemical blockade of
serotonin neurons as well as selective lesions in the
serotonin terminals led to a dramatic reduction of
the induced involuntary movements without coun-
teracting levodopa’s main effects.10,12,26,27 In addition,
serotonin receptor agonists have been shown to have
antidyskinetic effects in both rodent and nonhuman
primate models of dyskinesias.12,28
In humans, a recent clinical and PET imaging study
from our group showed that buspirone, a 5-HT1a par-
tial agonist, when administered acutely prior to levo-
dopa in patients with PD with LIDs, is able to
normalize levodopa-derived levels of synaptic dopa-
mine and to alleviate dyskinesias.12 Similarly, a recent
phase I/IIa clinical trial in patients with PD29 con-
firmed antidyskinetic effects of the 5-HT1a/5-HT1b
partial agonist eltoprazine following the promising re-
sults of the same drug in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)–treated macaques.12
Taken together, these studies suggest that the
development of LIDs is dependent on compromised
dopaminergic function and on aberrant serotonergic
function in the striatum.
A recent imaging study estimated midbrain-SERT
to striatal-DAT binding ratio in early-stage, drug-
naive patients with PD. The authors showed that
imbalanced ratios do not predict the development
of LIDs in early stages of the disease, but hypothe-
sized that imbalance ratios may occur at later stages
of PD.30
Our study suggests that the putaminal SERT-to-
DAT terminals ratio is a good index to quantify
in vivo the serotonergic over dopaminergic terminals’
activity. Using PET and SPECT imaging, we have
shown that the presence of LIDs is related to an imbal-
anced serotonergic-over-dopaminergic terminals density
ratio in the putamen. Our results indicate that while the
striatum becomes critically depleted of the dopaminergic
terminals with the progression of the disease, the sero-
tonergic terminals remain reasonably preserved to
uptake levodopa and release dopamine. Hence, the sero-
tonergic terminals in the striatummay start to contribute
to the development of dyskinesias once the dopaminer-
gic innervation becomes critically low.
Previous studies looking for clinical risk factors in
LIDs have shown that the occurrence of LIDs is
linked with younger age at onset of PD,31–33 as well
as with longer disease duration.32,34 The LIDs and
non-LIDs groups of our PD cohort were clinically
different (so that reached statistical significance) for
sex, age, disease duration, the duration on dopamin-
ergic medication, and LEDTotal. We performed sep-
arate analysis corrected for sex and found similar but
less significant results compared to our whole cohort
(male and female). Our dyskinetic patients with PD
had longer disease duration, had a younger age at
onset, and were treated with higher daily levodopa
doses. This may reflect that the 2 groups represent
2 different factions within our studied population,
which may have had an influence on the SERT-to-
DAT terminals ratio. Nonetheless, we did not find
any correlation between the SERT-to-DAT binding
ratios and the age at onset or the duration of dopa-
minergic medication. Hence, we propose that sex,
age, and duration of dopaminergic medication may
have not affected the outcome of our findings in this
cohort and that disease duration may indeed be a
good index to reflect the serotonergic over dopamin-
ergic terminals’ changes that occur in the striatum
during PD progression.
Serotonin-to-dopamine transporter binding ratio
increases as PD progresses and patients experience
dyskinesias. Our findings support the hypothesis that
the serotonergic terminals are involved in the occur-
rence of LIDs, once the dopaminergic innervation
in the striatum is critically low. There may be a
threshold during the progression of the disease that
dyskinesias occur; nonetheless, this study makes it
difficult to address this point. Future longitudinal
studies with SERT and DAT imaging in a larger
number of patients may be able to address this point
by studying the time from initiation of dopaminergic
medication to the first time dyskinesias are observed
in relation to serotonergic terminals’ activity. Future
clinical trials with highly selective 5-HT1A/B drugs as
antidyskinetic agents could also provide robust sup-
port to the above findings.
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